Medicine & Life Sciences
Non-Small Cell Lung Carcinoma
100%
Neoplasms
78%
Lung Neoplasms
54%
Pemetrexed
52%
gemcitabine
37%
Pharmacokinetics
34%
Maximum Tolerated Dose
33%
Therapeutics
32%
Drug Therapy
32%
Small Cell Lung Carcinoma
32%
Farnesyltranstransferase
28%
Sorafenib
28%
Survival
27%
Carboplatin
25%
Clinical Trials
23%
Cisplatin
21%
Mesothelioma
19%
tipifarnib
19%
Irinotecan
17%
Mitogen-Activated Protein Kinase Kinases
16%
Progression-Free Survival
16%
Bortezomib
15%
NSC 366140
15%
ErbB Receptors
15%
Paclitaxel
14%
Breast Neoplasms
14%
Appointments and Schedules
13%
Mutation
13%
Biomarkers
13%
Docetaxel
13%
Radiotherapy
12%
Apoptosis
12%
Safety
12%
Antineoplastic Agents
12%
lonafarnib
12%
Malignant Mesothelioma
11%
Transferases
11%
Pancreatic Neoplasms
11%
Protein-Tyrosine Kinases
11%
Bevacizumab
11%
Proteins
11%
Thorax
11%
Platinum
11%
Pharmaceutical Preparations
10%
National Cancer Institute (U.S.)
10%
Folic Acid Antagonists
10%
ras Proteins
9%
Confidence Intervals
9%
Neutropenia
9%
Topotecan
9%